Propranolol and breast cancer—a work in progress
Authors:
Open Access
- 18 June 2018
- journal article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 12, ed82
Abstract
The non-selective beta-blocker propranolol is a leading candidate for repurposing as a novel anti-cancer agent. Emerging evidence, including human data, suggests that there are multiple mechanisms of action particularly relevant to breast cancer. This editorial reviews a number of recent studies that show it has anti-metastatic activity that warrants clinical investigation, including investigation as a potential perioperative therapy in breast cancer.Keywords
This publication has 37 references indexed in Scilit:
- Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathwayJournal of Cancer Research and Therapeutics, 2014
- Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal womenBreast Cancer Research and Treatment, 2013
- Stimulation of Host Bone Marrow Stromal Cells by Sympathetic Nerves Promotes Breast Cancer Bone Metastasis in MicePLOS Biology, 2012
- Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Beta Blockers and Breast Cancer Mortality: A Population- Based StudyJournal of Clinical Oncology, 2011
- Improving Postoperative Immune Status and Resistance to Cancer MetastasisAnnals of Surgery, 2011
- The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast CancerCancer Research, 2010
- Surgical Stress Promotes Tumor Growth in Ovarian CarcinomaClinical Cancer Research, 2009
- Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor MetastasisAnnals of Surgical Oncology, 2008
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinomaNature Medicine, 2006